DocGo Stock

DocGo EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of DocGo (DCGO) as of Jun 23, 2026 is 2.54.In the previous year, EV/EBIT (Enterprise Value to EBIT) was 4.76 — a change of -46.6% (lower).

EV/EBIT

2.54

YoY

-46.6%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of DocGo is 2026 2.54 . EV/EBIT (Enterprise Value to EBIT) of DocGo was 2025 4.76 . It decreases by -46.6% lower compared to the previous year.

The DocGo EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2020
-5,343 base
Jan 1, 2021
4,597 base
Jan 1, 2022
2,269 base
Jan 1, 2023
3,854 base
Jan 1, 2024
1,617 base
Invalid Date
-103 base
Invalid Date
-121 base
YEARPRICE-TO-EBIT
2026 est -1,21
2025 est -1,03
2024 16,17
2023 38,54
2022 22,69
2021 45,97
2020 -53,43
Access this data via the Eulerpool API

DocGo Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides DocGo's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates DocGo's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots DocGo's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if DocGo grows earnings faster than its peers.

DocGo Stock analysis

What does DocGo do? The history of DocGo Inc began in 2014 when the idea was born to develop a mobile app for doctor appointment scheduling and health monitoring. The founders recognized a rising demand for faster and more convenient access to medical services. From this vision, DocGo Inc was created. DocGo Inc's business model includes a range of mobile applications that improve access to medical care. The main application is DocGo, which allows users to book doctor appointments and track and manage their health data. This app also offers a feature for monitoring chronic conditions such as diabetes or high blood pressure and automatically sends reports on the status of these conditions to the user's doctor. Another important product from DocGo is the telemedicine system, which allows users to receive early assessments and diagnoses from doctors through video and chat. This helps avoid many cases where patients need to physically visit a doctor, saving time and money. DocGo has also developed a mobile pharmacy app that allows patients to order their medications directly through the app and have them delivered to their homes. This app also has interactive features such as a reminder function that notifies the user when to take their medications. Another important aspect of DocGo is its integration with wearables, which allows users to measure and send their health data to the app in real time. DocGo also utilizes artificial intelligence and machine learning to identify health risks in users and provide recommendations for medications and treatments. In recent years, DocGo has expanded in various areas. The company has formed partnerships with major healthcare organizations and hospitals to create a broader network of care. DocGo has also developed an API that allows other companies to integrate their health data into the DocGo system. Overall, DocGo has made a significant contribution to improving access to medical care, particularly during the COVID-19 pandemic. By providing telemedicine and mobile pharmacy services, as well as managing health data, DocGo has helped democratize and enhance healthcare. DocGo is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DocGo stock

EV/EBIT (Enterprise Value to EBIT) of DocGo amounted to 4.76 2.54

Access this data via the Eulerpool API

Valuation — DocGo

All Key Metrics — DocGo